These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 27680564)

  • 1. Erratum to: Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin.
    Buta C; Benabou E; Lequoy M; Régnault H; Wendum D; Merabtene F; Chettouh H; Aoudjehane L; Conti F; Chrétien Y; Scatton O; Rosmorduc O; Praz F; Fartoux L; Desbois-Mouthon C
    J Exp Clin Cancer Res; 2016 Sep; 35(1):154. PubMed ID: 27680564
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib.
    Yonesaka K; Hirotani K; Kawakami H; Takeda M; Kaneda H; Sakai K; Okamoto I; Nishio K; Jänne PA; Nakagawa K
    Oncogene; 2016 Feb; 35(7):878-86. PubMed ID: 25961915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells.
    Kawakami H; Okamoto I; Yonesaka K; Okamoto K; Shibata K; Shinkai Y; Sakamoto H; Kitano M; Tamura T; Nishio K; Nakagawa K
    Oncotarget; 2014 Dec; 5(23):11847-56. PubMed ID: 25474137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine phosphorylation of PYK2 mediates heregulin-induced glioma invasion: novel heregulin/HER3-stimulated signaling pathway in glioma.
    van der Horst EH; Weber I; Ullrich A
    Int J Cancer; 2005 Feb; 113(5):689-98. PubMed ID: 15499613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
    Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K
    Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human EGF receptor (HER) family and heregulin members are differentially expressed in epidermal keratinocytes and modulate differentiation.
    De Potter IY; Poumay Y; Squillace KA; Pittelkow MR
    Exp Cell Res; 2001 Dec; 271(2):315-28. PubMed ID: 11716544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
    Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
    Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth.
    Gregory CW; Whang YE; McCall W; Fei X; Liu Y; Ponguta LA; French FS; Wilson EM; Earp HS
    Clin Cancer Res; 2005 Mar; 11(5):1704-12. PubMed ID: 15755991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential signaling by an anti-p185(HER2) antibody and heregulin.
    Le XF; Vadlamudi R; McWatters A; Bae DS; Mills GB; Kumar R; Bast RC
    Cancer Res; 2000 Jul; 60(13):3522-31. PubMed ID: 10910064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Forskolin increases neuregulin receptors in human Schwann cells without increasing receptor mRNA.
    Fregien NL; White LA; Bunge MB; Wood PM
    Glia; 2005 Jan; 49(1):24-35. PubMed ID: 15390106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The heregulin/human epidermal growth factor receptor as a new growth factor system in melanoma with multiple ways of deregulation.
    Stove C; Stove V; Derycke L; Van Marck V; Mareel M; Bracke M
    J Invest Dermatol; 2003 Oct; 121(4):802-12. PubMed ID: 14632199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct characteristics of heregulin signals mediated by HER3 or HER4.
    Weiss FU; Wallasch C; Campiglio M; Issing W; Ullrich A
    J Cell Physiol; 1997 Nov; 173(2):187-95. PubMed ID: 9365520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.
    Razumienko EJ; Scollard DA; Reilly RM
    J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.
    Zhou BB; Peyton M; He B; Liu C; Girard L; Caudler E; Lo Y; Baribaud F; Mikami I; Reguart N; Yang G; Li Y; Yao W; Vaddi K; Gazdar AF; Friedman SM; Jablons DM; Newton RC; Fridman JS; Minna JD; Scherle PA
    Cancer Cell; 2006 Jul; 10(1):39-50. PubMed ID: 16843264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of heregulin/HER3 in the primary culture of human urothelial cancer.
    Okuyama H; Yoshida T; Endo H; Nakayama M; Nonomura N; Nishimura K; Inoue M
    J Urol; 2013 Jul; 190(1):302-10. PubMed ID: 23313199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity.
    Nagumo Y; Faratian D; Mullen P; Harrison DJ; Hasmann M; Langdon SP
    Mol Cancer Res; 2009 Sep; 7(9):1563-71. PubMed ID: 19737968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. gamma-heregulin is the product of a chromosomal translocation fusing the DOC4 and HGL/NRG1 genes in the MDA-MB-175 breast cancer cell line.
    Wang XZ; Jolicoeur EM; Conte N; Chaffanet M; Zhang Y; Mozziconacci MJ; Feiner H; Birnbaum D; Pébusque MJ; Ron D
    Oncogene; 1999 Oct; 18(41):5718-21. PubMed ID: 10523851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms.
    Le XF; McWatters A; Wiener J; Wu JY; Mills GB; Bast RC
    Clin Cancer Res; 2000 Jan; 6(1):260-70. PubMed ID: 10656457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of inhibition effect of herceptin on interaction between heregulin and erbB receptors HER3/HER2 by single-molecule force spectroscopy.
    Shi X; Xu L; Yu J; Fang X
    Exp Cell Res; 2009 Oct; 315(16):2847-55. PubMed ID: 19497323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.